Arcturus Therapeutics
ARCT
42 hedge funds and large institutions have $47.3M invested in Arcturus Therapeutics in 2019 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 2 closing their positions.
950% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 2
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
167% more capital invested
Capital invested by funds: $17.7M → $47.3M (+$29.6M)
83% more funds holding
Funds holding: 23 → 42 (+19)
18.01% more ownership
Funds ownership: 14.31% → 32.32% (+18%)
36% less call options, than puts
Call options by funds: $385K | Put options by funds: $604K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DI
DFPG Investments
Sandy,
Utah
|
+$4.98M |
| 2 |
TC
TownSquare Capital
Provo,
Utah
|
+$4.88M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.32M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.92M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highline Capital Management
New York
|
-$1.39M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$28K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$3.39K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
-$1.08K |
ARCT Hedge Fund Activity: Q3 2019 in Review
42 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2019, worth a combined $47.3M — up 167% from $17.7M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ARCT positions and 2 closed out — a net gain of 19 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was DFPG Investments, opening a new position worth an estimated $4.98M. The largest seller was Highline Capital Management, cutting an estimated $1.39M.
- 42 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2019, up from 23 in Q2 2019.
- Funds reported $47.3M of Arcturus Therapeutics stock for Q3 2019, up 167% quarter-over-quarter.
- 21 funds opened new Arcturus Therapeutics positions in Q3 2019 and 2 closed out, a net change of +19 holders.
- The largest Arcturus Therapeutics buyer in Q3 2019 was DFPG Investments, an estimated $4.98M added.
- The largest Arcturus Therapeutics seller in Q3 2019 was Highline Capital Management, an estimated $1.39M sold.
Based on aggregated 13F filings for Q3 2019.